Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Pirtobrutinib in Previously Treated CLL/SLL
NCT07218341Phase 4Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2026
- Primary completion
- May 2030
- Countries
- 17
01
Overview
A Phase 4 trial of pirtobrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Eli Lilly and Company. Started Mar 2026; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07218341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218341.